A closer look into biotech dealmaking

In recent quarters, dealmaking has picked up noticeably, despite there not being any big-ticket acquisitions. The cash holdings of several large pharmaceutical companies have also swelled, giving them greater resources to pursue dealmaking.


  • After a lengthy drought, could biotech M&A be on the upswing?
  • The top questions facing biotech M&A in 2022
  • Venture investors turn to safer bets after biotech correction



Share the Post:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to our use of all cookies, however, you may visit “Cookies Setting” to provide a controlled consent.

Privacy Policy